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Objectives: To evaluate European physicians’ treatment preferences for prevent-
ing skeletal-related events (SREs) in patients with bone metastases from solid 
tumors. MethOds: Physicians completed an online discrete-choice experiment 
survey consisting of 10 choices between pairs of hypothetical medication profiles 
for a putative patient. Each profile included five attributes within a pre-defined range 
(based on prescribing information for the available bone-targeted agents [BTA]): 
months until first SRE (10, 18 and 28 months); months until worsening of pain (3, 6 
and 10 months); annual risk of osteonecrosis of the jaw (ONJ; 0, 1 and 5%); annual risk 
of renal impairment (0, 4 and 10%); and mode of administration (oral tablet, subcuta-
neous injection, 15-minute infusion and 120-minute infusion). Choice questions were 
based on an experimental design with known statistical properties. The survey was 
pretested with 8 physicians using open-ended interviews. A separate main-effects 
random parameters logit model was estimated for each country. Results: Physicians 
from France (n= 191), Germany (n= 192) and the UK (n= 197) completed the survey. 
Among the attributes included in the survey, months until first SRE and the risk of 
renal impairement were the most important attributes in France and the UK, whereas 
in Germany months until first SRE and a delay in worsening of pain were the most 
important. For all these attributes, better levels were significantly preferred to worse 
levels (p< 0.05). In all three countries, a 120-minute infusion every 4 weeks was the 
least preferred mode of administration (p< 0.05). The annual risk of ONJ was judged by 
physicians to be the least important attribute in all three countries. cOnclusiOns: 
Physicians generally make treatment decisions regarding choice of BTA for patients 
with bone metastases based on intent to delay the onset of SREs, managing risk of 
renal impairment and preventing the worsening of pain.
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Objectives: Several bone-targeted agents (BTAs) are approved for the prevention 
of skeletal related events (SREs). Nurses work closely with physicans and patients 
in managing the disease. Whilst influencing treatment decisions, nurses prefer-
ences for alternative treatment options have not been assessed. This study evalu-
ated US nurses’ preferences for treatment attributes in preventing SREs among 
patients with bone metastases from solid tumors. MethOds: Nurses completed a 
web-enabled discrete-choice experiment survey consisting of 10 choices between 
pairs of hypothetical medication and patient profiles. Each profile included six 
medication attributes within a pre-defined range (primarily based on prescribing 
information and real-world practice): months until first SRE (10, 18 and 28 months); 
months until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis of 
the jaw (ONJ; 0, 1 and 5%); annual risk of renal impairment (0, 4 and 10%); mode of 
administration (subcutaneous injection, 15-minute infusion and 120-minute infu-
sion); and out-of-pocket cost to patients ($25, $75, $150 and $330). Choice questions 
were based on an experimental design with known statistical properties. The survey 
was pretested with 6 nurses using open-ended interviews. A main-effects random 
parameters logit model was estimated. Results: A total of 196 US nurses com-
pleted the survey. Among the attribute levels included in the survey, out-of-pocket 
costs to patients, risk of renal impairement, and months until first SRE were the 
most important attributes. For all attributes, better levels were significantly pre-
ferred to worse levels (p< 0.05) except that no difference was observed between 0% 
and 1% ONJ attribute. Annual risk of ONJ was perceived by nurses to be the least 
important attribute. cOnclusiOns: When working with physicians and patients 
on the choice of BTAs for patients with bone metastases, out-of-pocket costs to 
patients, managing the risk of renal impairment and delaying time to first SRE are 
the primary foci for nurses.
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Objectives: Among the bone-targeted agents (BTAs) currently approved for the pre-
vention of skeletal-related events (SREs), several characteristics may be considered 
by physicians when making treatment decisions. This study evaluated US physi-
cians’ treatment preferences for preventing SREs in patients with bone metastases 
from solid tumors. MethOds: Physicians treating patients with bone metasta-
ses completed a web-enabled discrete-choice experiment survey consisting of 10 
choices between pairs of hypothetical medication and patient profiles. Each profile 
included six medication attributes within a pre-defined range (primarily based on 
prescribing information and real-world practice): months until first SRE (10, 18 and 
28 months); months until worsening of pain (3, 6 and 10 months); annual risk of 
osteonecrosis of the jaw (ONJ; 0%, 1% and 5%); annual risk of renal impairment (0%, 
4% and 10%); mode of administration (subcutaneous injection, 15-minute infusion 
and 120-minute infusion every 4 weeks); and out-of-pocket cost to patients ($25, 
$75, $150 and $330). Choice questions were based on an experimental design with 
known statistical properties. The survey was pretested with 8 physicians using 
open-ended interviews. A main-effects random parameters logit model was esti-
mated. Results: A total of 200 US physicians completed the survey. Among the 
attribute levels included, out-of-pocket cost to patients, months until first SRE and 
the risk of renal impairment were the most important attributes. For those attrib-
utes, better levels (outcomes) were significantly preferred to worse levels (P < 0.05). 
For mode of administration, subcutaneous injection was preferred over 15-minute 
infusion every 4 weeks (P < 0.05). cOnclusiOns: When making treatment deci-
sions regarding choice of BTA for patients with bone metastases, out-of-pocket cost 
to patients, delaying the onset of SREs and managing the risk of renal impairment 
are the primary foci for physicians.
Patient selection was random. The basic condition for inclusion in the study was the 
availability of data necessary to meet the costs. The number of patients at this stage 
of the study was already 42 people. Age at diagnosis was 9 months to 12 years, the 
median age of the patients was 6,4 ± 5,6 years. All of the patients were in the hospi-
tal with their parents of working age. In the calculations have been included: - GRP 
Chelyabinsk region (Gross Regional Product-14 USD per day per capita ) and GDP 
(Gross Domestic Product-44,4 USD per day per capita ), which amounted on average in 
2008-2012. The formula for the calculation of total costs:E $ = Nd x GRP / GDP (Nd-the 
number of days of disability) Results: Comparing the various cost components of 
treatment revealed that the indirect costs are 66% of the total amount of all expenses 
for medical treatment. State losses caused by non-working period of hospitalized for 
care people and non-produced Gross Regional Product are 7758,5 ± 1076,1 USD per 
capita. Losses of GDP are 21449,6 ± 3748,8 USD per capita. cOnclusiOns: The for-
mation of regional budgets should be done with consideration of big loss connected 
with disability of people hospitalized for the care of the a sick child, adjusted for and 
with GRP/GDP taken into account of big potion non-medical costs.
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Objectives: To examine the trends in radiation therapy (RT) utilization by a popula-
tion based breast cancer cohort in Ontario, Canada. MethOds: The provincial can-
cer registry maintains cancer specific databases and provided a breast cancer cohort 
based on diagnosis dates from April 1, 2005 to March 31, 2010. Staging information 
was also available. The cohort was then linked, by their encrypted health card num-
ber, to linkable administrative datasets that are maintained by the Institute for 
Clinical Evaluative Sciences (ICES) such as RT utilization. Results: An all female 
breast cancer cohort (N= 39,656) was identified over a five-year timeframe and the 
average age was 61.6 ± 14.0 years. Approximately, two thirds (N= 25,225) of patients 
received RT and staging information was available for 22,988 patients (stage I = 
9,541; stage II = 8,516; stage III = 4,050; and stage IV = 881). Patients had an average 
of 1.4 ± 0.7 (stage I) number of RT courses, 1.8 ± 1.1 (stage II), 2.5 ± 1.3 (stage III), and 
2.8 ± 2.4 (stage IV). The percent ratio of conventional RT to intensity modulated RT 
(IMRT) was 70.9%:16.6% (stage I), 71.6%:11.3% (stage II), 74.6%:4.6% (stage III), and 
72.7%:12.6% (stage IV). For the non-IMRT cohort with a primary cancer (N= 30,887), 
the average number of fractions per course was 18.1 ± 9.2. cOnclusiOns: From 
2005 – 2010, almost two thirds of a Canadian female breast cancer cohort received 
RT and the average number of courses increased with stage. A similar trend was 
observed with the type of RT (coventional RT utilization increased with stage) but 
peaked at stage III and decreased at stage IV, likely due to palliation. The next step 
is to apply unit costs to the number of fractions per subgroup and to also obtain 
RT-planning and radiation therapist times.
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Objectives: Breast cancer (BC) is the most common cancer affecting women and, 
despite advances in treatment, is still the leading cause of cancer death among 
women worldwide. Approximately 20%-25% of the women diagnosed with BC will 
have HER2-positive disease and those with metastatic disease (mBC) have a 5-year 
life expectancy of only 24%. Recently, pertuzumab (P) was approved as a new thera-
peutical option for first line HER2-positive mBC in Brazil. This study aims to define 
the proportion of BC patients that would be eligible for pertuzumab+trastuzumab+
chemotherapy (P+T+C) combination therapy in São Paulo state by analyzing retro-
spectively (2000-March 2013) the Fundação Oncocentro (FOSP) cancer patient registry 
(Registro Hospitalar de Câncer – RHC). MethOds: Raw data of cancer cases reported 
from 2000-March 2013 was taken from the FOSP-RHC and mined according to the 
inclusion criteria of the CLEOPATRA trial. Only women with histologically/cytologi-
cally confirmed diagnosis of BC (ICD-50) and reported TNM classification at diagnosis 
were included in the analysis. P+T+C therapy eligible patients were those reported 
as stage IV at diagnosis (de novo mBC) or stages 0, I, II and III with evidence of pro-
gression at last tumour assessment (recurrent cases), excluding ones with evidence 
of central nervous system (CNS) metastasis. Was considered that all patients in the 
database would test for HER2 status and positivity rate was taken from literature 
(25%). Results: During the analysis period 59,095 BC cases with TNM classification 
at diagnosis were reported. 4,660 cases were considered de novo mBC and 7,378 cases 
were considered as recurrent. According to the positivity rate 3,010 patients would be 
eligible for P+T therapy which accounts for approximately 5.1% of the overall cases 
of BC. cOnclusiOns: First-line HER2-positive mBC is a targeted, clearly defined and 
limited patient population where pertuzumab based regimen provides significant 
and clinically meaningful benefits in overall survival and progression-free-survival.
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